Evidence map›Paper›PMID 26472175›Full record

ArticleScientific reports2015

H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps.

Hang Xie, Xiu-Feng Wan, Zhiping Ye, Ewan P Plant, Yangqing Zhao, Yifei Xu, Xing Li, Courtney Finch, Nan Zhao, Toshiaki Kawano and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 157 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Update on the Efficacy of Vaccination on Host Immunity to Influenza Virus Infection.International archives of allergy and immunology · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Hang XieLaboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration (CBER/FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.
Xiu-Feng WanDepartment of Basic Sciences, College of Veterinary Medicine, Mississippi State University, 240 Wise Center, Mississippi State, MS 39762.
Zhiping YeLaboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration (CBER/FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.
Ewan P PlantLaboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration (CBER/FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.
Yangqing ZhaoLaboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration (CBER/FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.
Yifei XuDepartment of Basic Sciences, College of Veterinary Medicine, Mississippi State University, 240 Wise Center, Mississippi State, MS 39762.
Xing LiLaboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration (CBER/FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.
Courtney FinchLaboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration (CBER/FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.
Nan ZhaoDepartment of Basic Sciences, College of Veterinary Medicine, Mississippi State University, 240 Wise Center, Mississippi State, MS 39762.
Toshiaki KawanoLaboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration (CBER/FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.
Olga ZouevaLaboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration (CBER/FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.
Meng-Jung ChiangLaboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration (CBER/FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.
Xianghong JingLaboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration (CBER/FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.
Zhengshi LinLaboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration (CBER/FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.
Anding ZhangLaboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration (CBER/FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.
Yanhong ZhuLaboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration (CBER/FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.
Center for Biologics Evaluation and Research · USUnited States Food and Drug Administration · USMississippi State University · US

Funding

Training and Mentoring Core P20GM103476 · NIGMS · UNIVERSITY OF SOUTHERN MISSISSIPPI · PI MICHAEL R GARRETT · 2012 to 2026
$60.2M
Genome Based Influenza Vaccine Strain Selection using Machine LearningR01AI116744 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI WAN, XIUFENG HENRY · 2015 to 2019
$1.9M
NIAID NIH HHS R01 AI116744NIAID NIH HHS R01AI116744NIGMS NIH HHS P20 GM103476
6 · The paper itself

Abstract

The poor performance of 2014-15 Northern Hemisphere (NH) influenza vaccines was attributed to mismatched H3N2 component with circulating epidemic strains. Using human serum samples collected from 2009-10, 2010-11 and 2014-15 NH influenza vaccine trials, we assessed their cross-reactive hemagglutination inhibition (HAI) antibody responses against recent H3 epidemic isolates. All three populations (children, adults, and older adults) vaccinated with the 2014-15 NH egg- or cell-based vaccine, showed >50% reduction in HAI post-vaccination geometric mean titers against epidemic H3 isolates from those against egg-grown H3 vaccine strain A/Texas/50/2012 (TX/12e). The 2014-15 NH vaccines, regardless of production type, failed to further extend HAI cross-reactivity against H3 epidemic strains from previous seasonal vaccines. Head-to-head comparison between ferret and human antisera derived antigenic maps revealed different antigenic patterns among representative egg- and cell-grown H3 viruses characterized. Molecular modeling indicated that the mutations of epidemic H3 strains were mainly located in antibody-binding sites A and B as compared with TX/12e. To improve vaccine strain selection, human serologic testing on vaccination-induced cross-reactivity need be emphasized along with virus antigenic characterization by ferret model.

Indexed as

AdultAnimalsAntigens, ViralChildCross ReactionsFerretsHemagglutination Inhibition TestsHumansImmune SeraInfluenza A Virus, H3N2 SubtypeInfluenza, HumanInfluenza VaccinesLectinsModels, MolecularProtein Structure, TertiaryVaccinationAntigens, Viralhemagglutinin IImmune SeraInfluenza VaccinesLectins

Identifiers

PMID26472175
PMCPMC4607887
OpenAlexW2395836201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.